The results of this study clearly demonstrated that the preoperative pembrolizimab + FOLFOX enhances the immune response with increased expression of PD‐L1 (PD‐L1 CPS ≥10, p = 0.0078) and CD8 (CD8 ≥5%, p = 0.0059), augmented the anti‐tumor efficacy of the combination treatment, also enhances adjuvant treatment benefits and thereafter the overall DFS and OS. The gene discussed is CD274; the disease is neoplasm.